Accepted Manuscript



A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial

Marin H. Kollef, MD, Jean-Damien Ricard, MD, Damien Roux, MD, Bruno Francois, MD, Eleni Ischaki, MD, Zsolt Rozgonyi, MD, Thierry Boulain, MD, Zsolt Ivanyi, MD, Gál János, MD, Denis Garot, MD, Firas Koura, MD, Epaminondas Zakynthinos, MD, George Dimopoulos, MD, Antonio Torres, MD, Wayne Danker, MD, A. Bruce Montgomery, MD

PII: S0012-3692(16)62463-7

DOI: 10.1016/j.chest.2016.11.026

Reference: CHEST 835

To appear in: *CHEST*

Received Date: 8 September 2016

Revised Date: 6 October 2016

Accepted Date: 2 November 2016

Please cite this article as: Kollef MH, Ricard JD, Roux D, Francois B, Ischaki E, Rozgonyi Z, Boulain T, Ivanyi Z, János G, Garot D, Koura F, Zakynthinos E, Dimopoulos G, Torres A, Danker W, Montgomery AB, A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial, *CHEST* (2016), doi: 10.1016/j.chest.2016.11.026.

Abstract: 248
Text: 2970

A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial

Marin H. Kollef, MD[1], Jean-Damien Ricard, MD[2], Damien Roux, MD[2], Bruno Francois, MD[3], Eleni Ischaki, MD[4], Zsolt Rozgonyi, MD[5], Thierry Boulain MD[6], Zsolt Ivanyi MD[7], Gál János MD [7], Denis Garot MD[8], Firas Koura, MD[9], Epaminondas Zakynthinos, MD[10], George Dimopoulos, MD[11] , Antonio Torres, MD[12], Wayne Danker, MD[13], A. Bruce Montgomery, MD[14]

[1]Washington University School of Medicine, Saint Louis, Missouri, USA; [2]Inserm, IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité, Paris, France - AP-HP, Hopital Louis Mourier, Service de Reanimation Medico-Chirurgicale, Colombes; [3]Inserm CIC-1435 & UMR 1092, Réanimation Polyvalente, CHU, Limoges, France; [4]General Hospital of Athens "Evangelismos", Athens, Greece; [5]Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary; [6]Hôpital de La Source, Orléans France; [7]Semmelweis University, Budapest, Hungary; [8]CHRU Bretonneau, Tours, France; [9]Kentucky Lung Clinic Hazard, Kentucky, USA; [10]University General Hospital of Larisa, Larisa Greece; [11]National and Kapodistrian University of Athens, Greece; [12] Department of Pulmonology, Hospital Clinic, IDIBAPS, CIBERES, University of Barcelona, Spain; [13]Wayne Danker, Parexel Corp. Research Triangle Park, North Carolina, USA; [14]Cardeas Pharma Corp., Seattle, Washington, USA.

Running Title: Amikacin fosfomycin aerosol for bacterial pneumonia

Conflict of Interest Disclosures: A. Bruce Montgomery is the chief executive officer of Cardeas Pharma. Dr. Kollef's effort was supported by the Barnes-Jewish Hospital Foundation. The remaining authors have no conflicts to report.

Corresponding Author:
Marin H. Kollef, MD
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine
4523 Clayton Avenue, Campus Box 8052
St. Louis, MO 63110
kollefm@wustl.edu